Effect of Beta-Blockers on Mortality after Myocardial Infarction in Adults with COPD

Published Online: Thursday, January 16, 2014
Follow Pharmacy_Times:
Jennifer Quint, clinical lecturer in epidemiology at the London School of Hygiene and Tropical Medicine, and Liam Smeeth, professor of clinical epidemiology at the London School of Hygiene and Tropical Medicine, discuss their BMJ study of UK COPD patients who have experienced a first myocardial infarction and the impact of beta-blocker therapy on mortality.

Related Articles
Although proton pump inhibitors are widely used, they are not without risks.
Similar to the DAPT trial on dual antiplatelet therapy beyond a year, the PEGASUS-TIMI 54 trial examined longer-term duration of ticagrelor therapy.
Everyday walking is the most commonly reported problematic daily activity for patients with chronic obstructive pulmonary disease (COPD).
Warfarin remains a cornerstone anticoagulant for a number of reasons that include its low cost at the pharmacy counter.
Latest Issues
$auto_registration$